Tumor-associated myeloid cells are believed to promote tumor development by stimulating tumor growth, angiogenesis, invasion, and metastasis. Tumor-associated myeloid cells that coexpress endothelial and myeloid markers represent a proangiogenic subpopulation known as vascular leukocytes. Recently, we and others had shown that tumor-derived TNFa promotes local tumor growth and vascularity. Our data suggested that tumor growth is in part due to TNFa-mediated increased numbers of tumor-associated vascular leukocytes (i.e., myeloid-endothelial biphenotypic cells). The work detailed herein explored the mechanism by which TNFa mediates endothelial differentiation of myeloid cells. Our studies showed that fibronectin is a robust facilitator of endothelial differentiation of blood mononuclear cells in vitro. We have found that TNFa treatment of monocytes significantly increased expression of a 5 b 1 integrin, a major fibronectin receptor enriched on endothelial cells, leading to a consequent fourfold increase in fibronectin adhesion. Furthermore, TNFa-treated monocytes upregulated expression of endothelial markers, flk-1(VEGFR2/KDR) and VE-cadherin. Integrin a 5 subunit inhibitory antibodies blocked adhesion to fibronectin as well as consequent upregulation of flk-1 and VE-cadherin transcripts, implying a role for outside-in signaling by the a 5 b 1 integrin after binding fibronectin. Finally, treatment of mouse tumors with anti-a 5 antibodies reduced accumulation of tumor vascular leukocytes in vivo. Our studies suggest that tumor cell-derived TNFa constitutes a tumor microenvironment signal that promotes differentiation of tumor-associated monocytes toward a proangiogenic/provasculogenic myeloid-endothelial phenotype via upregulation of the fibronectin receptor a 5 b 1 . Mol Cancer Res; 9(6); 702-11. Ó2011 AACR.
Introduction
Myeloid cells are a major component of the inflammatory infiltrate frequently seen in primary tumors (1, 2) . Often in mice and in patients, the myeloid population can drive tumor progression by promoting neovascularization, metastasis, and immunosuppression (1) (2) (3) . Several groups, including our own, have shown that circulating human or mouse monocytes in culture can become endothelial-like cells. They are positive for flt-1 (VEGFR1), flk-1 (VEGFR2 or KDR), tie1, tie2, vWF, CD31, VE-cadherin (CD105), CD45 (panleukocyte), and CD14 (LPS receptor selectively expressed on monocytes) and exhibit an endothelial phenotype (network formation on Matrigel, migrate toward VEGF, synthesis of eNOS, and Weibel-Palade bodies; refs. [4] [5] [6] [7] . Myeloid to endothelial plasticity has also been shown in vivo in several preclinical models (8) (9) (10) (11) . In fact, monocytes are being explored as an ideal source for progenitor-based vascular tissue engineering because of their ease of isolation and ability to give rise to endothelial-like cells (12) .
More recent studies have identified a myeloid population present in human ovarian tumors that express endothelial antigens, such as VE-cadherin, P1H12, and flk-1 (13, 14) . Myeloid-endothelial biphenotypic populations (also called vascular leukocytes) were also identified in murine sarcoma and melanomas that comprised around 2% to 5% of tumorassociated leukocytes (6) . Isolated vascular leukocytes from mouse and human tumor tissue were capable of generating functional vessels when reimplanted in vivo within Matrigel plugs (15) , albeit at very low levels (15) (16) (17) . Although vascular leukocytes are hardly reported incorporating directly into blood vessels, they represent a myeloid population that promotes tumor growth by promoting tumor angiogenesis and decreasing tumor necrosis (15, 16) .
Thus far, little, if anything, is known about the molecular signals that are involved in myeloid to endothelial transition. We have recently published that TNFa significantly promotes endothelial differentiation of myeloid cells, both in vivo and in vitro (16) . This study is to investigate which mechanism is involved in this process. Many studies attempting to generate and/or measure endothelial progenitor cells have utilized short-term adhesion of mononuclear cells to fibronectin-coated dishes which primarily selects for endothelial differentiation of circulating monocytes (18) . This study presents data to suggest that TNFa upregulates leukocyte adhesion to fibronectin during culture in endothelial promoting media by increasing surface expression of a 5 b 1 integrins. Integrins are a family of heterodimeric transmembrane proteins that are critical in cell matrix adhesion, which is required for survival of many cell types (19, 20) . Integrin-mediated adhesion represents the primary effector of the proendothelial differentiation capacity of TNFa which requires TNFa receptors on monocytes and intact NF-kB signaling.
Material and Methods

Mice and cell lines
C57BL/6 (BL/6, wild type), flk-1/LacZ on C57BL/6 (BL/6) background were purchased from Jackson Laboratory. Mice homozygous mutant for TNFR1 or R2, or both on a BL/6 background are maintained by the PI as previously described (16) . Stably transfected 1 Â 10 6 murine B16F10 mouse melanoma cells (American Type Culture Collection) were implanted subcutaneously. To generate transplanted mice, BL/6 wild type, syngeneic littermates received 800 rads of preconditioning irradiation and were transplanted with bone marrow (BM) from flk-1/lacZ transgenic donors generating flk/lacZ/BMTs. After engraftment (2 months) mice were implanted with control or TNFa-producing B16F10 lines on both flanks. On each flank, cells were mixed with either control (CATAERWRC) or function-blocking (CRRETAWAC) peptide for a 5 b 1 (MIMOTOPES, 25 mmol) in 50% Matrigel (21, 22) . Tumors were collected 2 weeks after they were implanted. All experiments were done in accordance with Association for Assessment and Accreditation of Laboratory Animal Care guidelines and with Vanderbilt University Institutional Animal Care and Use Committee approval.
Stable transfections of tumor lines were done with pcDNA3 plasmid encoding TNFa cDNA driven by the CMV promoter carried out with Lipofectamine 2000 (Invitrogen Life Technologies). After selection for 14 days with 1,500 mg/mL G418 (Sigma), individual colonies were picked and maintained in media containing 500 mg/mL G418. Mouse TNFa secreted into culture media was measured as described by ELISA Quantikine kits (R&D systems).
Cell culture
Peripheral blood (PB) or BM mononuclear cells (MNC) were isolated as previously described (6) . MNCs were used to isolate CD14 þ (human) or CD11b þ (mouse) myeloid cells by using positive selection strategy with antibody-linked microbeads (Miltenyi Biotech) and a magnetic cell sorter device following manufacturer's protocol. Enriched myeloid populations (>99% purity) were plated at 2 Â 10 5 cells/cm 2 on fibronectin-coated plates in EGM-2 Bullet Kit system (Clonetics), in the absence or presence of recombinant human TNFa (Cell Sciences Corp.). For cell staining, cells were cultured on fibronectin-coated coverslips and analyzed by immunofluorescence by using species-specific anti-flk-1 (human, Reasearch Diagnostics) and anti-VE-cadherin (human, Cell Sciences). Myeloid-endothelial biphenotypic cell (vascular leukocyte) numbers were assessed by counting 5 random 40Â fields of VE-cadherin þ /flk-1 þ cells.
In vitro adhesion assay Cells were treated with or without TNFa for 2 days before assay. Round bottom 96-well plate were coated with 1% bovine serum albumin (BSA) or 10 mg/mL fibronectin in 50 mL PBS overnight at 4 C. Each well was loaded with 75,000 cells/50 mL PBS. For antibody blocking, cells were mixed with control IgG (immunoglobulin G; Biogend) or integrin a 5 (DSHB) antibody at 10 mg/mL before they were loaded in wells. Plate was set on top of ice for 1 hour to let cells adhere. After incubation, wells were washed with PBS until wells coated with BSA had very few cells remaining. Cells were fixed with 10% formalin and stained with crystal violet. After 3 times wash with distilled water, wells were air-dried for 5 minutes. Then cell-bound crystal violet was extracted by 0.5% Triton X-100 and read at 595 nm.
Fluorescence-activated cell sorting analysis
Human CD14 þ monocytes isolated from PB were cultured with or without TNFa for 4 days. Attached cells were detached with EDTA and washed with PBS/0.5% BSA prior to incubation with antibodies. Nonviable cells, identified by 7-aminoactinomycin D (7-AAD; Molecular Probes) staining, were excluded. Expression of integrins was assessed with monoclonal antibodies (mAb) to integrin a 5 and a v . Analysis was done on a LSMII flow cytometer Real-time RT-PCR RNA was isolated with Trizol (Invitrogen) following the manufacturer's instructions, and quality was confirmed by an A 260/280 ratio 1.9 or greater, as well as clear bands of 28S and 18S rRNA by gel electrophoresis. Following isolation, RNA was processed with the RNeasy RNA cleanup kit (Qiagen). cDNA was generated by using iScript cDNA synthesis kit (Bio-Rad) from 1 mg RNA. The cDNA was then used for real-time PCR by using SYBR-green iQ PCR supermix and run in an iCycler Real-Time PCR Thermal Cycler (Bio-Rad). Primer sequences are shown in Table 1 . The average cycle threshold from triplicate reactions was used to quantify the relative amount of mRNA present on the basis of a standard curve. Cycle thresholds for 18S rRNA transcripts were used to normalize between samples. Relative mRNA levels were expressed as means of the fold change over control. The results are from a minimum of 3 independent experiments.
Immunohistochemistry/fluorescence and morphometry
Paraffin-embedded tumor tissues were used for determination of F4/80 (Serotec). Cryosections were used for colocalization of F4/80 and b-gal (1:1,000; Novus). For immunofluorescent analysis, nuclei were counterstained by using 4 0 ,6-diamidino-2-phenylindole (Sigma). The images were visualized by using a Ziess Axioplan 2 Microscope (Carl Ziess MicroImaging). Images were photographed with a CoolSNAP Hq CCD Camera (Photometrics).
In vitro lacZ activity assay
Tumor samples harvested from flk-1/lacZ/BMT mice were homogenized (150 mmol/L NaCl, 10 mmol/L Tris, pH 7.5, 0.2% Triton X-100, and 1 mmol/L DTT), and samples were centrifuged at 14,000 Â g for 15 minutes, at 4 C. Protein concentration was quantified with BCA kit (Thermo). To quantify b-gal activity, 50 mg of homogenized tumor tissue protein was tested in triplicate, following the manufacturer protocol in the All-in-One b-gal assay reagent (Pierce). PBS alone, as well as samples obtained from wild-type mice, was used as negative control. Tumors from flk-1/lacZ mice served as positive control. 
Immunoblot analysis
Cells were lysed in radioimmunoprecipitation assay buffer. Cell lysates (20 mg of protein) were separated on NuPAGE Bis-Tris Mini Gel (Invitrogen) under reduced conditions and transferred to a filter. Primary antibodies for Erk, phospho-Erk, P38 MAPK (mitogen-activated protein kinase), phospho-p38 MAPK, and IkBa (cell signaling) were used to probe specific proteins. The blots were visualized by using an enhanced chemiluminescence substrate (PerkinElmer Inc).
Statistical analysis
The statistical significance between experimental groups and control was determined by paired or unpaired Student's t test or ANOVA, followed by Tukey posttest as designated by using GraphPad Prism. The value of P 0.05 was considered statistically significant and marked by asterisk in figures.
Results
Identification of fibronectin as modulator of TNFa-mediated myeloid to endothelial differentiation
Differentiation into endothelial-like cells, as verified by upregulation of VE-cadherin, flk-1, and vWF antigens by MNCs in culture, occur with higher efficiency in the presence of fibronectin as compared with collagens I or IV or vitronectin (23, 24) . In our previous study, we found that TNFa promoted myeloid to endothelial differentiation on fibronectin-coated surface (16) . To test whether TNFa increase endothelial differentiation of myeloid cells through a fibronectin-dependent manner, we plated human CD14 þ monocytes on tissue culture dishes precoated with fibronectin, vitronectin, or poly-L-lysine (which allows nonintegrinmediated adhesion) using serum-free medium. After 7 days, plates were washed to remove all nonadherent cells. Monocytes adhered and exhibited spindle-shaped morphology best on fibronectin (Fig. 1A) . Vitronectin also promoted robust cell adhesion, albeit the majority of the cells did not develop spindle-shaped morphology. Plating on poly-L-lysine virtually abrogated cell adhesion ( Fig. 1A and B ). The addition of TNFa enhanced by more than 2-fold the numbers of adherent, spindle-shaped cells, compared with control for both fibronectin and vitronectin (Fig. 1B) . To quantify what fraction of adherent spindle-shaped cells exhibited endothelial-specific antigens, we used immunofluorescence to assess expression of flk-1 (VEGFR2) and VE-cadherin antigens ( fibronectin substrate (Fig. 1D) . Upregulation of neither of the endothelial markers was observed in adherent cells on albumin-coated dishes after 7 days. Interestingly, plating monocytes on vitronectin generated flk-1 þ , adherent cells but did not result in significant expression of VE-cadherin within the designated time point, indicating that endothelial differentiation on vitronectin was at the very least delayed or incomplete as compared with fibronectin. These data showed that TNFa enhanced myeloid adhesion to both fibronectin and, to a lesser degree, vitronectin. However, endothelial differentiation of myeloid cells in culture occurred with high frequency on fibronectin, not vitronectin. This supported previously published data that showed a critical role of fibronectin in endothelial cell differentiation and both vascular embryonic development and adult angiogenesis (4, 8, 11) .
TNFa promoted a 5 transcript and cell surface expression on monocytes plated on fibronectin
The integrin a 5 b 1 serves as the major fibronectin receptor. a v b 1 and a 4 b 1 also overlap as fibronectin receptors (25) . Monocytes and endothelial cells exhibit different integrin and adhesion protein expression patterns (26) . To assess whether TNFa upregulated fibronectin-binding receptors, total RNA from human CD14 þ cells cultured in EGM-2 on fibronectin-coated dishes in 0, 10, or 40 ng/mL hTNFa for 3 days were subjected to real time reverse transcriptase PCR (RT-PCR) to detect integrin subunit expression. Both a 5 and a v transcripts were induced approximately 4-and 2.5-fold, respectively, by exposure to TNFa over control; whereas, transcripts of a 4 decreased approximately 10-fold with 40 ng/mL TNFa (P < 0.05; Fig. 2A ). Interestingly, a 4 transcripts decreased during endothelial differentiation in control samples, relative to uncultured CD14 cells, and were also undetectable in human umbilical vein endothelial cells, further supporting that this integrin is leukocyte, not endothelial, enriched (data not shown). Transcripts of b 1 and b 3 (data not shown) were not affected by TNFa treatment. As b 1 integrin subunits heterodimerize with multiple alpha subunit partners, they are less subject to regulation by gene expression (25) . We used flow cytometry to examine whether TNFa also resulted in a parallel increase in the cell surface expression of the a 5 subunit. TNFa treatment (40 ng/mL) resulted in approximately 2-fold increase in a 5 cell surface expression evident after 4 days in culture over control (Fig. 2B) . There was no significant change in expression of a v or b 1 . The a 5 expression in TNFa-treated cells was not statistically different from control after 6 days (data not shown), suggesting that TNFa accelerated the expression of the adhesion molecule early during the differentiation process, but the differences in levels did not persist over time in culture.
TNFa promoted monocyte adhesion to fibronectin and subsequent endothelial marker expression on a 5 -dependent manner
We assessed whether CD14 þ monocyte adhesion to fibronectin was modulated by the a 5 b 1 fibronectin receptor by using an antibody against a 5 that previously was shown to block receptor-ligand attachment (22, 27) . We observed significantly higher (>4-fold) attachment of monocytes to fibronectin-coated surfaces as compared with those coated with BSA ( Fig. 3A and B) . Furthermore, there was a statistically significant increase in monocyte cell attachment to fibronectin following pretreatment with TNFa for 2 days (Fig. 3A and B) . However, preincubation with antibody against a 5 (30 minutes, on ice) after cells had been pretreated with TNFa for 2 days in culture virtually abolished monocyte cell attachment to fibronectin (Fig. 3B, P < 0.05) . Interestingly, although the control IgG antibody had minimal impact on monocyte adhesion to fibronectin, it interfered with TNFa-mediated increase in monocyte adhesion to fibronectin (Fig. 3B) . We used the same function-blocking antibody, or mouse IgG control, to assess the role of a 5 b 1 on TNFa-induced endothelial differentiation of monocytes by quantifying levels of endothelial selective transcript levels in human CD14 þ monocytes cultured for 4 days with TNFa. Flk-1 and VE-cadherin transcripts were induced approximately 2.5-and 5-fold, respectively, over control (Fig. 4) . Induction of both transcripts were abrogated by coincubation with a 5 antibody, but not IgG control (Fig. 4 , P < 0.05). Together, these data suggested that TNFa-induced adhesion and endothelial differentiation of human CD14 þ monocytes on fibronectin were mediated primarily through the a 5 b 1 integrin.
integrin-blocking peptide diminishes BM-derived vascular cells in tumors in vivo
Because integrin a 5 b 1 modulated both monocyte adhesion to fibronectin and also TNFa-induced endothelial differentiation on that substrate, we designed in vivo experiments to assess the effects of blocking a 5 b 1 on myeloid to endothelial differentiation (i.e., generation of vascular leukocytes) in vivo. A cyclic peptide that specifically binds integrin a 5 b 1 , CRRETAWAC, was used as antagonist. We used a BM transplant (BMT) model in which lacZ is driven by flk-1 (an endothelial-specific marker) promoter to evaluate the role of the a 5 b 1 fibronectin receptor in generating BM-derived flk-1 þ vascular leukocytes in tumors (depicted in the Fig. 5A schematic) . In each mouse, the 2 flanks are implanted with the same tumor, but mixed with either control or blocking peptide. TNFaoverexpressing B16F10 tumors treated with scrambled control peptide had several b-gal-positive cell clusters, with most cells colocalizing with the F4/80 macrophage marker as shown by confocal microscopy (Fig. 5B, top  panel) . By contrast, TNFa-expressing tumors treated with the peptide antagonist of integrin a 5 b 1 had very few to no b-gal-positive cells (Fig. 5B, bottom panel) . To provide quantification of BM-derived flk-1 þ cells within tumors in the absence or presence of a 5 b 1 antagonists, we measured b-gal enzyme activity in the tumor homogenates. The average b-gal activity in tumors derived from lines expressing empty vector (control tumors) incubated with either a 5 b 1 -blocking peptide or scrambled peptide were not statistically different (Fig. 5C ). On the other hand, the average b-gal activity, as a surrogate marker for flk-1 þ cell content, detected in tumors generated from TNFaexpressing lines treated with blocking peptide was significantly less than those treated with control peptide (Fig. 5D ). These data suggested that blocking fibronectin adhesion and signaling within tumors blocked TNFainduced generation of flk-1 þ vascular leukocytes in vivo.
Involvement of NF-kB activation on TNFa-induced myeloid adhesion and endothelial differentiation on fibronectin
The regulation of expression of many genes by TNFa involves activation of the transcription factor NF-kB (28) . Within minutes following addition of TNFa, cytosolic NF-kB is released from its inhibitor IkB and translocated to the nucleus where it regulates gene expression (28) . The signaling mechanism involved in transduction of the multiple biochemical and biological effects of TNFa, particularly in myeloid differentiation, is poorly understood. On the other hand, endothelial differentiation from mononuclear cells has been linked to p38 and MAP/ERK kinase (MEK) activation (29) (30) (31) . To study the activation of these kinases, we checked their phosphorylation during myeloidendothelial differentiation in culture on different matrix substrates (with or without TNFa). Immunoblot analysis showed that unlike growing on BSA surface, monocytes growing on fibronectin showed enhanced Erk and p38 activity and maintained their activity after TNFa treatment (Fig. 6A) . As for NF-kB signal pathway, TNFa-induced degradation of IkB was detected on both substrates. However, growing the cells on fibronectin resulted in lower levels of IkB, which reflected higher activity of NF-kB signal pathway on fibronectin-coated surface.
To further identify whether these pathways are involved in TNFa-inducible adhesion or differentiation, we cultured CD14 þ monocytes in the presence or absence of specific inhibitors of these signaling pathways and quantified cell adhesion to fibronectin and differentiation. Inhibition of MEK or p38 slightly reduced monocyte adhesion to fibronectin. But TNFa still increased adhesion in presence of these 2 inhibitors. However, IkK inhibitor dramatically reduced monocyte adhesion of both control and TNFatreated cells (Fig. 6B) . When endothelial differentiation was assessed by immunofluorescent analysis for the expression of flk-1, both p38 and IkK inhibitors prevented spindle-shaped morphology (data not shown) and resulted in few to no immunopositive cells. MEK inhibitors, on the other hand, resulted in overall reduced numbers of flk-1 þ cells (Fig. 6C) . Taken together, NF-kB is implicated in both adhesion and differentiation of monocytes, whereas p38 may be important during myeloid-endothelial differentiation.
TNFR2 is primary mediator of TNFa-induced myeloid to endothelial differentiation
TNFa exerts its biological effects by binding and signaling through 2 distinct receptors, TNFR1 and TNFR2 (28) . Myeloid cells express both TNFR1 and TNFR2 (32, 33) . We sought to investigate whether TNFa induction of endothelial differentiation was dependent on the presence of TNFRs by carrying out real-time RT-PCR for flk-1 transcripts of CD11b þ monocytes isolated from wild type or mice lacking both TNFRs and cultured in endothelial inducing media for 2 days. Monocytes lacking TNFRs had a significant decrease in flk-1 transcripts than control monocytes (Fig. 7A) . We subsequently compared the differentiation capacity of CD11b þ monocytes isolated from TNFR1 À/À or TNFR2 À/À mice. Relative flk-1 transcript levels after 4 days of culture were significantly decreased by approximately 2-fold in TNFR2 À/À monocytes (Fig. 7B ). These data suggested not only that TNFRs were necessary for TNFa-induced endothelial differentiation of myeloid cells but that TNFR2 played a greater role in mediating the signaling. 
Discussion
The ability of CD14 þ human monocytes as well as mouse monocytes to differentiate into functional endothelium or endothelial-like cells has been shown by numerous studies (4-7). Generation of EC-like cells impacts key biological processes such as tissue repair and regeneration and cancer growth (12) . In human and mouse tumors, myeloid cells have been shown to generate proangiogenic myeloidendothelial biphenotypic cells (vascular leukocytes) as well as contribute to a small degree to functional tumor vasculature (6, 16, 34) . Several studies have used monocytes to facilitate vascular tissue engineering as well a cellular vehicle to target cancers (12, 35) . Because monocytes are far more abundant than CD34 þ progenitor cells, which also can generate endothelium, they may provide a readily available source from which to develop vascular and/or cancer cellular therapy.
Despite our recognition of the occurrence of myeloid to endothelial differentiation, little is known about the molecular signals that regulate this transition. In our previous study, we have identified TNFa as an important promoter of endothelial differentiation of myeloid cells, both in vitro and in vivo during mouse cancer growth (16) . In this study, we show that differentiation of monocyte/myeloid cells into endothelial-like cells occurs most efficiently on defined cell culture media in the presence of fibronectin matrix, which promotes both better adhesion and endothelial-like differentiation than vitronectin. We observed enhanced adhesion to fibronectin of myeloid cells treated with TNFa, which could be inhibited by integrin a 5 -blocking antibody. TNFa-enhanced adhesion is likely mediated by increased transcripts and cell surface expression of the fibronectin receptor, a 5 b 1 .
The expression of a 5 b 1 integrins is known to induce expression of VE-cadherin in endothelial cells and may serve as part of the differentiation cue in this study of monocytederived endothelial-like cells (36, 37) . a v b 3 , another fibronectin-binding integrin, is also implicated in this process, albeit its expression is induced somewhat later than a 5 b 1 during development and, therefore, is not the initiating signal to promote endothelial-specific gene expression (37) . In our study, we did not see a major TNFa-induced expression of a v . Myeloid cells exhibit high expression of a 4 b 1 (VLA4), also a major fibronectin-binding integrin that has been shown to be important for monocyte adhesion and invasion into tumors (26) . TNFa actually resulted in a dosedependent reduction of a 4 with a concomitant increase in a 5 , which is far more upregulated on proliferative endothelial cells (38) . Our studies point to a unique role for a 5 b 1 . There are 2 functional TNF receptors. TNFR1 is expressed by most cells and TNFR2 is present on immune cells, as well as monocytes (32, 33) . Differentiation of myeloid cells isolated from wild-type and TNFR1 À/À and/or TNFR2 À/À mice elucidated that the effect of TNFa for endothelial differentiation of mouse monocytes was primarily mediated by TNFR2. Among the signal pathway that may be altered by TNFa, NF-kB signal pathway showed to be the most important one that is required for endothelial differentiation as blocking NF-kB signal pathway with IkK inhibitor in human monocytes almost completely inhibited myeloid cell adhesion and differentiation. By contrast, inhibiting p38 and MEK signal pathway did not inhibit myeloid adhesion to fibronectin as much as inhibiting NF-kB signal pathway, they both inhibited myeloid differentiation dramatically, which showed their importance in myeloid-endothelial differentiation. Immunoblot analysis showed that TNFa can activate NF-kB signal pathway on both BSA-and fibronectin-coated surface. However, TNFa reduced p38 and MEK/Erk signal pathway noticeably on BSA but not on fibronectin-coated surface. These data indicate that TNFa enhanced a 5 b 1 and fibronectin interaction sustained p38 and MEK/Erk signal pathway activation. Together with the activated NF-kB signal pathway, these signal transductions promoted myeloid to endothelial differentiation. Figure 8 provides a schematic of the mechanism of TNFa-induced endothelial differentiation supported by our studies.
Several studies have highlighted the central role of a 5 b 1 integrin-fibronectin interaction in the promotion of tumor neovasculature (21) . Blocking antibodies have been successfully used to target this interaction and reduce tumor growth (39) . Although a 5 b 1 is abundantly expressed in tumor vasculature, our studies show that this a 5 b 1 -fibronectin interaction is also important for myeloid to endothelial transition. We and others have shown that myeloid/ endothelial vascular leukocytes promote angiogenesis and promote tumor growth (15) (16) (17) . Hence, our work, in addition to shedding light on cellular and signaling mechanism of myeloid to endothelial transition, presents a new mechanism by which inhibition of a 5 b 1 integrin signaling may avert tumor angiogenesis and growth.
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